About Alligator Bioscience
Alligator is a clinical-stage research and development-based biotechnology company that develops antibody-based drugs for cancer treatment. The Company specializes in the development of tumor-directed immunotherapies, specifically agonistic mono- and bispecific antibodies. Immunotherapy is a type of treatment that stimulates the patient’s own immune system to cure cancer. ‘Tumor-directed’ means that the drug is administered or designed in such a way that the immunostimulatory effect can be localized to the tumor. This results in a good safety and efficacy profile.
Alligator is active in the drug development phases ranging from concept and early drug discovery up to and including Phase 2 clinical studies involving patients. This includes the development and optimization of novel drug candidates, evaluation of preclinical efficacy and safety, and finally confirmatory clinical studies in cancer patients. Alligator was founded in 2001 and is based in Medicon Village in Lund, Sweden.
The case
Alligator’s development portfolio comprises the drug candidates mitazalimab, ATOR-1017 (evunzekibart), ALG.APV-527, ATOR-4066 as well as the Neo-X-Prime™ drug concept, all of which are designed for the treatment of metastatic cancer.
On January 29, 2024, the Company released positive top-line results from the OPTIMIZE-1 study. The study achieved its primary endpoint with the top-line results demonstrating a confirmed Objective Response Rate (“ORR”) of 40.4 percent, an unconfirmed ORR of 50.9 percent and a disease control rate (DCR) of 79 percent in 57 evaluable patients, as per the Response Evaluation Criteria in Solid Tumors (RECIST 1.1). This compares favorably to the ORR of 31.6 percent reported in a similar patient population treated with FOLFIRINOX alone. The cut-off time for analysis was November 14, 2023, with a median follow-up duration of 12.7 months. At the time of the analysis, a total of 29 (51 percent) patients were still alive, of these 18 (32 percent) were still on treatment. The longest ongoing treatment duration was 23 months and three patients demonstrated complete remission of their target lesions. For further information on the data from the study, please refer to the Company’s press release published on January 29, 2024.
Website: https://alligatorbioscience.se/en/